4th Annual Genome Editing USA Congress (Delivered Digitally)
Hyatt Regency Boston, One Avenue de Lafayette, Boston, Massachusetts, United States, 02111
In light of the current COVID-19 situation, Oxford Global have made the decision to deliver NextGen Omics US as a fully digital event. The dates and timings for the event will continue as normal, however presentations will be hosted virtually.
350+ end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical & biotech companies.
3 outstanding programmes bringing together Europe’s key genomics experts in Next Generation Sequencing, Single Cell Analysis, Genome Editing.
80+ case studies, solution & technology presentations & 2 interactive workshops over the 2 days.
07 April 2019 – Day One
- Genome Editing Technologies & Techniques
- Drug Discovery & Development Applications in In Vivo Therapeutics
08 April 2019 – Day Two
- Drug Discovery & Development – Target Identification and Validation
- Non-Human Models in Diagnostics & Therapeutics
View Agenda: http://bit.ly/2rLMzeL
George Church, Professor of Genetics, Health Sciences and Technology, Wyss Institute at Harvard University
Tod Woolf, Founder and Chief Executive Officer, ETAGEN Pharma, Inc.
Svetlana Belyanskaya, Scientific Leader, Encoded Library Technologies, GlaxoSmithKline
Salil Desai, Chief Executive Officer, PhenomYX Luhan Yang, Co-Founder and Chief Scientific Officer, eGenesis
Nadeem Sarwar, Founder & President, Eisai Center for Genetics Guided Dementia Discovery, Eisai
John Reidhaar-Olson, Senior Director, Pfizer
Oleg Iartchouk, Director, Genomics and Next-Generation Sequencing, Novartis